Beyond the commonly used immunotherapy options, toripalimab, a humanized IgG4κ monoclonal antibody targeting the PD-1 receptor, has demonstrated efficacy as a second-line treatment for patients with EGFR-mutant advanced NSCLC in a phase II study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.